Publications 2017-10-27T15:59:43+00:00

Relevant publications

The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.
Nielsen CF, van Putten SM, Lund IK, Melander MC, Nørregaard KS, Jürgensen HJ, Reckzeh K, Christensen KR, Ingvarsen SZ, Gårdsvoll H, Jensen KE, Hamerlik P, Engelholm LH, Behrendt N.
Oncotarget. 2017; 8(27):44605-44624

Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180.
Engelholm LH, Melander MC, Hald A, Persson M, Madsen DH, Jürgensen HJ, Johansson K, Nielsen C, Nørregaard KS, Ingvarsen SZ, Kjaer A, Trovik CS, Laerum OD, Bugge TH, Eide J, Behrendt N.
J Pathol. 2016;238(1):120-33

The collagen receptor uPARAP/Endo180 in tissue degradation and cancer (Review).
Melander MC, Jürgensen HJ, Madsen DH, Engelholm LH, Behrendt N.
Int J Oncol. 2015 Oct;47(4):1177-88

Endocytic collagen degradation: a novel mechanism involved in protection against liver fibrosis.
Madsen DH, Jürgensen HJ, Ingvarsen S, Melander MC, Vainer B, Egerod KL, Hald A, Rønø B, Madsen CA, Bugge TH, Engelholm LH, Behrendt N.
J Pathol. 2012 M;227(1):94-105

Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy.
Curino AC, Engelholm LH, Yamada SS, Holmbeck K, Lund LR, Molinolo AA, Behrendt N, Nielsen BS, Bugge TH.
J Cell Biol. 2005;169(6):977-85

uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion.
Engelholm LH, List K, Netzel-Arnett S, Cukierman E, Mitola DJ, Aaronson H, Kjøller L, Larsen JK, Yamada KM, Strickland DK, Holmbeck K, Danø K, Birkedal-Hansen H, Behrendt N, Bugge TH.
J Cell Biol. 2003;160(7):1009-15

A urokinase receptor-associated protein with specific collagen binding properties.
Behrendt N, Jensen ON, Engelholm LH, Mørtz E, Mann M, Danø K.
J Biol Chem. 2000;275(3):1993-2002